KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Total Current Liabilities (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Total Current Liabilities for 16 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 61.54% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, down 61.54% year-over-year, with the annual reading at $6.0 million for FY2025, 61.54% down from the prior year.
  • Total Current Liabilities hit $6.0 million in Q4 2025 for Arbutus Biopharma, up from $5.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $32.9 million in Q4 2022 to a low of $5.0 million in Q2 2025.
  • Historically, Total Current Liabilities has averaged $18.4 million across 5 years, with a median of $19.9 million in 2024.
  • Biggest five-year swings in Total Current Liabilities: surged 384.22% in 2022 and later crashed 77.77% in 2025.
  • Year by year, Total Current Liabilities stood at $11.2 million in 2021, then skyrocketed by 192.82% to $32.9 million in 2022, then tumbled by 31.56% to $22.5 million in 2023, then plummeted by 30.55% to $15.6 million in 2024, then plummeted by 61.54% to $6.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for ABUS at $6.0 million in Q4 2025, $5.2 million in Q3 2025, and $5.0 million in Q2 2025.